Neurocrine Biosciences, Inc.
NBIX
NASDAQ·Healthcare·Biotechnology·Mkt cap $15.9B
$158.35
▲ +0.35%
P/E
22.88
Mkt Cap
$15.9B
52-Wk Range
$122.14–$186.12
52-Week Range
$122.14 - $186.12
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market-leading INGREZZA with strong tardive dyskinesia franchise and brand recognition
- Diversified product portfolio across multiple therapeutic areas reducing revenue concentration risk
- Strategic partnerships with major pharmaceutical companies providing development and commercialization support
- Experienced management team with proven track record in specialty pharmaceutical development and commercialization
- Focused pipeline targeting high-value indications with significant unmet medical needs
Bear Case
2 risks
- Low volatility (beta 0.4).
- Growth premium of 1.7x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
Strong revenue growth (21% YoY)
Value
Growth premium of 1.7x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Momentum
Weak
-5.4% over 3m
Quality
Excellent
High-growth business (34% revenue growth, 98% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying NBIX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 30, 2026
Reported EPS of $1.39 vs $1.65 consensus (-15.8% surprise). Revenue of $959.0M vs $891.2M expected (+7.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-15.8%
Revenue trend · last 8Q
—
+22%
+11%
+16%
+28%
+28%
+42%
+39%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$622.1M
$627.7M
$572.6M
$687.5M
$794.9M
$805.5M
$814.5M
$959.0M
Margins · last 8Q
Gross
97.6%
Operating
15.8%
Profit
15.1%
Wall Street consensus
17 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 3, 2026
vs Industry
How NBIX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related